NCT05897216

Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029

A Randomized, Open-label, Single Oral Dosing, Two-sequence, and Two-period Crossover Study to Evaluate the Pharmacokinetics and Safety Between Administration of CKD-383 and Co-administration of CKD-501, D745, D150, and D029

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D745, D150 and D029 for Healthy Subjects in Fed State

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	CKD-383	QD, PO
DRUG	CKD-501, D745, D150, D029	QD, PO

Timeline

• Start date: 2023-07-14
• Primary completion: 2023-07-23
• Completion: 2023-08-08
• First posted: 2023-06-09
• Last updated: 2024-01-23

Locations

1 site across 1 country: South Korea